Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Blood (2017) 130 (15): 1713–1721.

https://doi.org/10.1182/blood-2017-04-780155

Published: 2017

Includes: Supplemental data

Journal Articles

Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients

Blood (2014) 124 (21): 310.

https://doi.org/10.1182/blood.V124.21.310.310

Published: 2014

Journal Articles

Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients

Ann L. Van de Velde, Sébastien Anguille, Philippe Beutels, PhD, Suzy Dom, Ingrid Cornille, Griet Nijs, Viggo F Van Tendeloo, Evelien L. Smits, Anke Verlinden, Alain P. Gadisseur, Wilfried A Schroyens, Zwi N Berneman, MD PhD

Blood (2014) 124 (21): 1322.

https://doi.org/10.1182/blood.V124.21.1322.1322

Published: 2014

Journal Articles

Prevention Of Relapse In Acute Myeloid Leukemia By Dendritic Cell Vaccination: Report on a Phase II Study With 29 Patients

Zwi N. Berneman, MD, PhD, FRCP, Ann Van de Velde, MD, Sébastien Anguille, MD, Yannick Willemen, MD, Wilfried A. Schroyens, MD, PhD, Alain P. Gadisseur, MD, PhD, Inge Vrelust, MD, Griet Nijs, MT, Barbara Stein, MSc, Nathalie Cools, PhD, Ronald Malfait, MD, Marie-Berthe Maes, PharmD, PhD, Katrien Vermeulen, PhD, Viggo F. Van Tendeloo, PhD, Evelien L. Smits, PhD

Blood (2013) 122 (21): 236.

https://doi.org/10.1182/blood.V122.21.236.236

Published: 2013

Journal Articles

Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),

Blood (2011) 118 (21): 3312.

https://doi.org/10.1182/blood.V118.21.3312.3312

Published: 2011

Journal Articles

WT1-Targeted Dendritic Cell Vaccination as A Post-Remission Treatment to Prevent Full Relapse In Acute Myeloid Leukemia

Blood (2010) 116 (21): 16.

https://doi.org/10.1182/blood.V116.21.16.16

Published: 2010

Journal Articles

Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms’ Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid Leukemia

Zwi N. Berneman, Ann Van de Velde, Ann Van Driessche, Nathalie Cools, Barbara Stein, Griet Nijs, Katrien Vermeulen, Katrien Pieters, Wilfried A. Schroyens, Alain P. Gadisseur, Inge Vrelust, I. Jolanda de Vries, David A. Price, Yusuke Oji, Haruo Sugiyama, Viggo F. Van Tendeloo

Blood (2008) 112 (11): 830.

https://doi.org/10.1182/blood.V112.11.830.830

Published: 2008

Journal Articles

Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms’ Tumor Protein WT1: A Phase I/II Trial.

Zwi N. Berneman, MD, PhD, Ann Van Driessche, M.Sc., Ann Van de Velde, M.D., Griet Nijs, M.T., Tessa Braeckman, M.Sc., Barbara Stein, M.Sc, Katrien Vermeulen, Ph.D., Katrien Pieters, Ph.D., Alain P. Gadisseur, M.D., Ph.D, Wilfried A. Schroyens, M.D., Ph.D., I. Jolanda de Vries, Ph.D., David A. Price, Ph.D., Viggo F. Van Tendeloo, Ph.D.

Blood (2007) 110 (11): 158.

https://doi.org/10.1182/blood.V110.11.158.158

Published: 2007

Journal Articles

Double-Stranded RNA Acts as a Strong Danger Signal in Human Myeloid Leukemia Cells Leading to Increased Immunogenicity.

Zwi N. Berneman, MD, PhD, Evelien L.J.M. Smits, M.Sc., Peter Ponsaerts, Ph.D., Nathalie Cools, M.Sc., Ann L.R. Van de Velde, M.D., Alain P. Gadisseur, M.D., Ph.D., Wilfried A. Schroyens, M.D., Ph.D., Viggo F.I. Van Tendeloo, Ph.D.

Blood (2006) 108 (11): 5203.

https://doi.org/10.1182/blood.V108.11.5203.5203

Published: 2006

Journal Articles

Routine Measurement of Endogenous Thrombin Potential (ETP) To Assess Hemostatic Function in Patients with Liver Cirrhosis.

Alain P. Gadisseur, MD, PhD, Jeoffrey Schouten, MD, Sven Franque, MD, Marc Van der Planken, MD, Peter Michielsen, MD, PhD, Zwi N. Berneman, MD, PhD

Blood (2006) 108 (11): 4014.

https://doi.org/10.1182/blood.V108.11.4014.4014

Published: 2006

Journal Articles

Comparison between Endogenous Thrombin Potential (ETP) and INR To Assess Liver Function in Patients with Liver Cirrhosis.

Jeoffrey Schouten, MD, Alain P. Gadisseur, MD, PhD, Sven Franque, MD, Marc Van der Planken, MD, Peter Michielsen, MD, PhD, Zwi N. Berneman, MD, PhD

Blood (2006) 108 (11): 4015.

https://doi.org/10.1182/blood.V108.11.4015.4015

Published: 2006

NARROW

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients

Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients

Prevention Of Relapse In Acute Myeloid Leukemia By Dendritic Cell Vaccination: Report on a Phase II Study With 29 Patients

Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),

WT1-Targeted Dendritic Cell Vaccination as A Post-Remission Treatment to Prevent Full Relapse In Acute Myeloid Leukemia

Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms’ Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid Leukemia

Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms’ Tumor Protein WT1: A Phase I/II Trial.

Double-Stranded RNA Acts as a Strong Danger Signal in Human Myeloid Leukemia Cells Leading to Increased Immunogenicity.

Routine Measurement of Endogenous Thrombin Potential (ETP) To Assess Hemostatic Function in Patients with Liver Cirrhosis.

Comparison between Endogenous Thrombin Potential (ETP) and INR To Assess Liver Function in Patients with Liver Cirrhosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only